Logo image of AVTX

AVALO THERAPEUTICS INC (AVTX) Stock Fundamental Analysis

NASDAQ:AVTX - Nasdaq - US05338F3064 - Common Stock - Currency: USD

3.75  -0.16 (-4.09%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to AVTX. AVTX was compared to 562 industry peers in the Biotechnology industry. While AVTX has a great health rating, there are worries on its profitability. While showing a medium growth rate, AVTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AVTX has reported negative net income.
In the past year AVTX has reported a negative cash flow from operations.
AVTX had negative earnings in each of the past 5 years.
In the past 5 years AVTX always reported negative operating cash flow.
AVTX Yearly Net Income VS EBIT VS OCF VS FCFAVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -41.34%, AVTX perfoms like the industry average, outperforming 54.45% of the companies in the same industry.
AVTX's Return On Equity of -46.84% is fine compared to the rest of the industry. AVTX outperforms 67.08% of its industry peers.
Industry RankSector Rank
ROA -41.34%
ROE -46.84%
ROIC N/A
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVTX Yearly ROA, ROE, ROICAVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Gross Margin of AVTX (201.13%) is better than 99.82% of its industry peers.
In the last couple of years the Gross Margin of AVTX has grown nicely.
AVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 201.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
AVTX Yearly Profit, Operating, Gross MarginsAVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

AVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
AVTX has more shares outstanding than it did 1 year ago.
AVTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVTX Yearly Shares OutstandingAVTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
AVTX Yearly Total Debt VS Total AssetsAVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -2.02, we must say that AVTX is in the distress zone and has some risk of bankruptcy.
AVTX has a Altman-Z score (-2.02) which is comparable to the rest of the industry.
AVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.02
ROIC/WACCN/A
WACC10.02%
AVTX Yearly LT Debt VS Equity VS FCFAVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 19.96 indicates that AVTX has no problem at all paying its short term obligations.
AVTX's Current ratio of 19.96 is amongst the best of the industry. AVTX outperforms 94.31% of its industry peers.
A Quick Ratio of 19.96 indicates that AVTX has no problem at all paying its short term obligations.
AVTX has a better Quick ratio (19.96) than 94.31% of its industry peers.
Industry RankSector Rank
Current Ratio 19.96
Quick Ratio 19.96
AVTX Yearly Current Assets VS Current LiabilitesAVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.23% over the past year.
The Revenue for AVTX has decreased by -77.08% in the past year. This is quite bad
Measured over the past years, AVTX shows a very negative growth in Revenue. The Revenue has been decreasing by -42.05% on average per year.
EPS 1Y (TTM)94.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.11%
Revenue 1Y (TTM)-77.08%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.60% on average over the next years. This is quite good.
Based on estimates for the next years, AVTX will show a very strong growth in Revenue. The Revenue will grow by 108.44% on average per year.
EPS Next Y96.57%
EPS Next 2Y40.43%
EPS Next 3Y25.47%
EPS Next 5Y14.6%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y108.44%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AVTX Yearly Revenue VS EstimatesAVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2029 2030 2031 2032 100M 200M 300M 400M
AVTX Yearly EPS VS EstimatesAVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2K -4K -6K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVTX Price Earnings VS Forward Price EarningsAVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVTX Per share dataAVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

AVTX's earnings are expected to grow with 25.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.43%
EPS Next 3Y25.47%

More info and screens

0

5. Dividend

5.1 Amount

AVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVALO THERAPEUTICS INC

NASDAQ:AVTX (5/23/2025, 9:14:39 PM)

3.75

-0.16 (-4.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners63.55%
Inst Owner Change17.77%
Ins Owners5.29%
Ins Owner Change43.35%
Market Cap40.61M
Analysts87.14
Price Target32.13 (756.8%)
Short Float %0.5%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-946.48%
Min EPS beat(2)-1889.97%
Max EPS beat(2)-2.98%
EPS beat(4)0
Avg EPS beat(4)-3403.42%
Min EPS beat(4)-11614.9%
Max EPS beat(4)-2.98%
EPS beat(8)3
Avg EPS beat(8)-1969.42%
EPS beat(12)5
Avg EPS beat(12)-1307.29%
EPS beat(16)7
Avg EPS beat(16)-984.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.56%
PT rev (3m)-4.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.6%
EPS NY rev (1m)2.3%
EPS NY rev (3m)-4.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 92.09
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-24.52
EYN/A
EPS(NY)-4.61
Fwd EYN/A
FCF(TTM)-4.53
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS0.04
BVpS12.28
TBVpS11.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.34%
ROE -46.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 201.13%
FCFM N/A
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.96
Quick Ratio 19.96
Altman-Z -2.02
F-Score5
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)52.94%
Cap/Depr(5y)33.74%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.11%
EPS Next Y96.57%
EPS Next 2Y40.43%
EPS Next 3Y25.47%
EPS Next 5Y14.6%
Revenue 1Y (TTM)-77.08%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y108.44%
EBIT growth 1Y-96.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-59.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.9%
OCF growth 3YN/A
OCF growth 5YN/A